Article Text

Download PDFPDF
Case report
The first case record of a female patient with bubonic lymphogranuloma venereum (LGV), serovariant L2b
  1. Stephan P Verweij1,
  2. Sander Ouburg1,
  3. Harry de Vries3,
  4. Servaas A Morré1,2,
  5. Cees J W van Ginkel4,
  6. Hanna Bos5,
  7. Fré W Sebens6
  1. 1Laboratory of Immunogenetics, Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
  2. 2Institute of Public Health Genomics, Department of Genetics and Cell Biology, Research Institutes CAPHRI and GROW, University of Maastricht, Maastricht, The Netherlands
  3. 3Department of Surgery, Deventer Hospital, Deventer, The Netherlands
  4. 4Department of Dermatology, Deventer Hospital, Deventer, The Netherlands
  5. 5Municipal Health Service (GGD Gelre-IJssel), Deventer, The Netherlands
  6. 6Department of Microbiology, Deventer Hospital, Deventer, The Netherlands
  1. Correspondence to Dr Servaas Antonie Morre, VU University Medical Center, Department of Pathology, Laboratory of Immunogenetics (LoI), ZH-3E-48, To: S.A. Morré, Head LoI, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands; samorretravel{at}


Since 2003, a lymphogranuloma venereum epidemic has been reported in The Netherlands and other European countries. This epidemic is caused by Chlamydia trachomatis serovariant L2b and has only been seen in men having sex with men. The authors investigated a woman presenting with a bubo in her right groin. The authors showed by real-time PCR that the woman was infected with C trachomatis, serovariant L2b. This is the first reported case study of a female patient with bubonic lymphogranuloma venereum caused by serovariant L2b, which was probably contracted via her bisexual male partner.

  • Chlamydia trachomatis
  • LGV
  • bubonic L2b
  • female
  • first case
  • laboratory diagnosis
  • risk factors
  • infectious disease
  • serotypes
  • syndromic management
  • systematic reviews
  • epidemiology (clinical)

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests None.

  • Patient consent Manuscript is fully anonymised. The patient cannot be identified from this manuscript.

  • Provenance and peer review Not commissioned; externally peer reviewed.